|
Glomerular Filtration Rate
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Sex-specific and pleiotropic effects underlying kidney function identified from GWAS meta-analysis.
|
31015462 |
2019 |
|
Low density lipoprotein cholesterol measurement
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Genetic analyses of diverse populations improves discovery for complex traits.
|
31217584 |
2019 |
|
Serum total cholesterol measurement
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Genetic analyses of diverse populations improves discovery for complex traits.
|
31217584 |
2019 |
|
Vital capacity
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Allergic Reaction
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Eleven loci with new reproducible genetic associations with allergic disease risk.
|
29679657 |
2019 |
|
Red Blood Cell Count measurement
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Serum total cholesterol measurement
|
|
0.700 |
GeneticVariation
|
GWASCAT |
A large electronic-health-record-based genome-wide study of serum lipids.
|
29507422 |
2018 |
|
Blood Protein Measurement
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Low density lipoprotein cholesterol measurement
|
|
0.700 |
GeneticVariation
|
GWASCAT |
A large electronic-health-record-based genome-wide study of serum lipids.
|
29507422 |
2018 |
|
Low density lipoprotein cholesterol measurement
|
|
0.700 |
GeneticVariation
|
GWASCAT |
The impact of low-frequency and rare variants on lipid levels.
|
25961943 |
2015 |
|
Venous Thrombosis
|
|
0.700 |
GeneticVariation
|
GWASDB |
Caution in interpreting results from imputation analysis when linkage disequilibrium extends over a large distance: a case study on venous thrombosis.
|
22675575 |
2012 |
|
Coronary Artery Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Genetically instrumented blood lead was not associated with CAD (odds ratio (OR) 1.01 per effect size of log transformed blood lead, 95% confidence interval (CI) 0.97, 1.05), blood pressure (systolic -0.18 mmHg, 95% CI -0.44 to 0.08 and diastolic -0.03 mmHg, 95% CI -0.09 to 0.15) or diabetes (OR 0.98, 95% CI 0.92 to 1.03) using MR-PRESSO estimates corrected for an outlier SNP (rs550057) from the highly pleiotropic gene ABO.
|
31690775 |
2019 |
|
Diabetes Mellitus
|
|
0.010 |
GeneticVariation
|
BEFREE |
Genetically instrumented blood lead was not associated with CAD (odds ratio (OR) 1.01 per effect size of log transformed blood lead, 95% confidence interval (CI) 0.97, 1.05), blood pressure (systolic -0.18 mmHg, 95% CI -0.44 to 0.08 and diastolic -0.03 mmHg, 95% CI -0.09 to 0.15) or diabetes (OR 0.98, 95% CI 0.92 to 1.03) using MR-PRESSO estimates corrected for an outlier SNP (rs550057) from the highly pleiotropic gene ABO.
|
31690775 |
2019 |
|
Diabetes
|
|
0.010 |
GeneticVariation
|
BEFREE |
Genetically instrumented blood lead was not associated with CAD (odds ratio (OR) 1.01 per effect size of log transformed blood lead, 95% confidence interval (CI) 0.97, 1.05), blood pressure (systolic -0.18 mmHg, 95% CI -0.44 to 0.08 and diastolic -0.03 mmHg, 95% CI -0.09 to 0.15) or diabetes (OR 0.98, 95% CI 0.92 to 1.03) using MR-PRESSO estimates corrected for an outlier SNP (rs550057) from the highly pleiotropic gene ABO.
|
31690775 |
2019 |